Immutep (IMMP) has released an update.
Immutep Limited, a biotech firm, has reported promising clinical trial outcomes for efti in metastatic breast cancer and head and neck squamous cell carcinoma, with the latter showing a 26.9% response rate in PD-L1 negative tumors. The company is also gearing up for mid-2024 clinical trials of its preclinical autoimmune disease candidate, IMP761, and has a strong cash position expected to last into early 2026.
For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.
